Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Change in Cash: 2020-2025

Historic Change in Cash for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to $40.4 million.

  • Silence Therapeutics' Change in Cash rose 172.43% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 108.98%. This contributed to the annual value of $52.5 million for FY2024, which is 2866.70% up from last year.
  • As of Q3 2025, Silence Therapeutics' Change in Cash stood at $40.4 million, which was up 273.05% from -$23.3 million recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' Change in Cash peaked at $74.0 million during Q1 2024, and registered a low of -$56.7 million during Q1 2025.
  • Moreover, its 3-year median value for Change in Cash was -$4.3 million (2024), whereas its average is $1.5 million.
  • Within the past 5 years, the most significant YoY rise in Silence Therapeutics' Change in Cash was 16,706.50% (2022), while the steepest drop was 1,253.11% (2022).
  • Silence Therapeutics' Change in Cash (Quarterly) stood at $3.0 million in 2021, then crashed by 1,253.11% to -$34.9 million in 2022, then spiked by 94.44% to -$1.9 million in 2023, then surged by 2,085.72% to $38.5 million in 2024, then skyrocketed by 172.43% to $40.4 million in 2025.
  • Its Change in Cash was $40.4 million in Q3 2025, compared to -$23.3 million in Q2 2025 and -$56.7 million in Q1 2025.